The target antigens of the FDA licensed ADCs are CD19, CD22, CD30, CD33, and CD79b in hematological malignancies and HER2, trop2, nectin4, tissue factor, and folate receptor alpha (FRα) in solid cancers as illustrated in Table 1. This evidence concerns the gene FOLR1 and hematologic disorder.